Tenofovir Amibufenamide, a rising star in chronic hepatitis B treatment: How to achieve significant therapeutic effects with low dosage?
2026-01-13 Written by DengyueMed Tenofovir Amibufenamide (Hengmu®) is a next-generation tenofovir prodrug independently developed in China for the treatment of chronic hepatitis B (CHB). Designed with optimized molecular structure and enhanced liver targeting, Tenofovir Amibufenamide delivers potent antiviral efficacy at a significantly lower dose, while offering a favorable long-term...
0 Comments 0 Shares 4K Views 0 Reviews
TagInTime - Privacy-First Social Network https://tagintime.com